biphenyl-2-carbohydroxamic acid | 36828-13-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: biphenyl-2-carbohydroxamic acid
• 英文别名: N-hydroxy-[1,1'-biphenyl]-2-carboxamide；o-Phenylbenzohydroxamsaeure；o-Phenylbenzhydroxamsaeure；N-hydroxybiphenyl-2-carboxamide；N-hydroxy-2-phenylbenzamide
• CAS: 36828-13-4
• 化学式: C₁₃H₁₁NO₂
• 分子量: 213.236
• InChiKey: ZHSDLNXUORTYIN-UHFFFAOYSA-N

物化性质

• 熔点：
  132-136 °C(Solv: chloroform (67-66-3))
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  biphenyl-2-carbohydroxamic acid 在 potassium tert-butylate 、 溴 、 sodium carbonate 作用下， 以 乙醇 、 水 、 苯 为溶剂， 反应 2.0h， 生成 甲基2-联苯羧酸酯
  参考文献：
  名称：

  Glover, Stephen A.; Goosen, Andre; McCleland, Cedric W., Journal of the Chemical Society. Perkin transactions I, 1984, # 10, p. 2255 - 2260

  摘要：

  DOI：
• 作为产物：
  描述：

  二氢-3-(异十二碳烯基)呋喃-2,5-二酮 在 盐酸羟胺 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 吡啶 为溶剂， 以3%的产率得到biphenyl-2-carbohydroxamic acid
  参考文献：
  名称：

  [EN] INHIBITORS OF HISTONE DEACETYLASE
  [FR] INHIBITEURS DE L'HISTONE DÉACÉTYLASE

  摘要：

  这项发明涉及化合物和用于抑制HDAC酶活性的方法。更具体地，该发明提供了符合式(I)、(I)和N-氧化物、水合物、溶剂合物、药用可接受盐、前药和其复合物、外消旋和手性混合物、非对映异构体和对映体的化合物，其中L、M、n、R、W、X和Y如规范中定义的。

  公开号：

  WO2009055917A1
• 作为试剂：
  描述：

  苯甲酰乙酸乙酯 、 potassium tert-butylate 、 2-溴苯乙酮 在 biphenyl-2-carbohydroxamic acid 、 乙酸乙酯 、 水 、 Brine 、 Sodium sulfate-III 、 正己烷 作用下， 以 四氢呋喃 为溶剂， 反应 1.67h， 以to afford compound 69 (0.812 g, 67% yield) as a yellow oil的产率得到ethyl 2-benzoyl-4-oxo-4-phenylbutanoate
  参考文献：
  名称：

  Inhibitors of histone deacetylase

  摘要：

  本发明涉及化合物和方法，用于抑制HDAC酶活性。更具体地，本发明提供了式(I)、(I)和N-氧化物、水合物、溶剂化物、药学上可接受的盐、前药和复合物，以及它们的外消旋体和内消旋体混合物、对映体和非对称体，其中L、M、n、R、W、X和Y如规范中所定义。

  公开号：

  US08673911B2

文献信息

• Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
  申请人：Barta E. Thomas

  公开号：US20050009838A1

  公开（公告）日：2005-01-13

  This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A 1 , A 2 , Y, E 1 , E 2 , E 3 , and R x are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.

  这项发明通常涉及蛋白酶抑制剂（也称为“蛋白酶”），更具体地涉及对哌啶基和哌嗪基磺酰甲基羟肟酸的抑制作用，其中包括抑制基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或聚集素酶活性。这些羟肟酸通常在结构上对应于以下公式： （其中A 1 ，A 2 ，Y，E 1 ，E 2 ，E 3 和R x 如本说明书中所定义），并进一步包括这些化合物的盐。这项发明还涉及这些羟肟酸的组合物，合成这些羟肟酸的中间体，制备这些羟肟酸的方法，以及治疗与MMP活性和/或聚集素酶活性相关的病症（特别是病理性病症）的方法。
• Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
  申请人：McDonald J. Joseph

  公开号：US20050209278A1

  公开（公告）日：2005-09-22

  This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A 1 , A 2 , Y, E 1 , E 2 , E 3 , and R x are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.

  这项发明通常涉及蛋白酶抑制剂（也称为“蛋白酶”），更具体地涉及哌啶基和哌嗪基磺酰甲基羟肟酸，该类化合物在结构上抑制基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或聚集素酶活性。这类羟肟酸通常对应以下结构式： （其中A1、A2、Y、E1、E2、E3和Rx如本说明书中所定义），还包括这类化合物的盐。这项发明还涉及这类羟肟酸的组合物、合成这类羟肟酸的中间体、制备这类羟肟酸的方法，以及治疗与MMP活性和/或聚集素酶活性相关的疾病（特别是病理性疾病）的方法。
• Electrochemical Formation of <i>N</i>-Acyloxy Amidyl Radicals and Their Application: Regioselective Intramolecular Amination of sp² and sp³ C–H Bonds
  作者：Sheng Zhang、Lijun Li、Mengyu Xue、Ruike Zhang、Kun Xu、Chengchu Zeng

  DOI：10.1021/acs.orglett.8b00981

  日期：2018.6.15

  Electrochemical generation of N-acyloxy amidyl radicals via an inner-sphere electron-transfer process is described for the first time. With NaBr as the catalyst and electrolyte, the in situ generated amidyl radicals undergo intramolecular C(sp2/sp3)–H aminations to give lactams with unprecedented regio- and chemoselectivities. Moreover, the synthetic utility of current method is demonstrated by the

  首次描述了通过内球电子转移过程电化学生成N-酰氧基酰胺基。以NaBr为催化剂和电解质，原位生成的酰胺基自由基经过分子内C（sp 2 / sp 3）-H胺化反应，得到具有前所未有的区域选择性和化学选择性的内酰胺。此外，通过PJ34和Phenaglaydon的合成证明了当前方法的合成效用。
• Matrix metalloproteinase inhibitors
  申请人：Holmes Ian

  公开号：US20060235074A1

  公开（公告）日：2006-10-19

  Compounds of Formula (I): wherein: R 1 is optionally substituted —C 4-12 alkyl, —C 2-10 alkylcycloalkyl, —C 2-6 alkylheterocycloalkyl, —C 2-6 alkylaryl, optionally substituted 5- or 6-membered aryl or heteroaryl with the proviso that R 2 in not pyridinyl; Z is a bond, CH 2 , O, S, SO, SO 2 , NR 4 , OCR 4 R 5 or CR 4 R 5 O; or Z, R 1 and Q together form an optionally substituted fused tricyclic group; Q is an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X is COR 3 ; R 2 is CONH 2 , CO 2 H, CO 2 R 7 , SO 2 R 7 or SO 2 NR 8 R 9 , with the proviso that R 2 is not CO 2 R 7 , when X is CONH 2 ; R 3 is OR 6 or NR 8 R 9 ; R 4 and R 5 each independently is H, C 1-6 alkyl or C 1-4 alkylaryl; R 6 is H or C 1-6 alkyl; R 7 is C 1-6 alkyl; and R 8 and R 9 each independently is H or C 1-6 alkyl; or R 8 and R 9 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; or physiologically functional derivatives thereof, with the proviso that formula (I) compounds are not: [3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid and 3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid diethyl ether; butanedioic acid [3-methoxy-4-(phenylmethoxy)phenyl]; or butanedioic acid [4-(phenylmethoxy)phenyl]; and with the proviso that when R 1 is C 4-12 alkyl, Z is other than a bond, O or CH 2 ; and physiologically functional derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs) are described.

  式(I)的化合物：其中：R1是可选取代的—C4-12烷基，—C2-10烷基环烷基，—C2-6烷基杂环烷基，—C2-6烷基芳基，可选取代的5-或6-成员芳基或杂芳基，但R2不是吡啶基；Z是键，CH2，O，S，SO，SO2，NR4，OCR4R5或CR4R5O；或Z，R1和Q一起形成可选取代的融合三环基团；Q是可选取代的5-或6-成员芳基或杂芳基环；X是COR3；R2是CONH2，CO2H，CO2R7，SO2R7或SO2NR8R9，但当X是CONH2时，R2不是CO2R7；R3是OR6或NR8R9；R4和R5各自独立地是H，C1-6烷基或C1-4烷基芳基；R6是H或C1-6烷基；R7是C1-6烷基；R8和R9各自独立地是H或C1-6烷基；或R8和R9与它们所附着的氮原子一起形成一个可选取代的5-或6-成员环，该环可能包括1个或多个进一步选择的杂原子，包括O、S和N；或其生理学功能衍生物，但式(I)化合物不包括：[3-(乙酰氨基)-4-环己基苯基]-丁二酸和[3-(乙酰氨基)-4-环己基苯基]-丁二酸二乙醚；丁二酸[3-甲氧基-4-(苯基甲氧基)苯基]；或丁二酸[4-(苯基甲氧基)苯基]；以及其制备方法，含有它们的制药配方和作为基质金属蛋白酶酶（MMPs）抑制剂的用途。
• Isoform Selective HDAC Inhibitors
  申请人：Kozikowski Alan P.

  公开号：US20100196502A1

  公开（公告）日：2010-08-05

  One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising an HDAC inhibitor of the invention; and kits comprising a an HDAC inhibitor of the invention.

  本发明的一个方面涉及选择性同工酶HDAC抑制剂。还提供了一种使癌细胞对放疗的细胞毒性效应敏感的方法。本发明还提供了治疗癌症、神经系统疾病和疟疾的方法。此外，本发明还提供包含本发明的HDAC抑制剂的制药组合物；以及包含本发明的HDAC抑制剂的试剂盒。